For many years, the Medical Device Directive (MDD), published on July 12, 1993, formed the regulatory basis for medical devices in the European Union. With technological progress, growing market complexity, and several serious safety incidents, it became clear that the MDD no longer met current requirements. Consequently, the EU initiated a reform process. This process culminated in the introduction of the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR). Their adoption was decided on May 25, 2017, and they ultimately entered into force on May 26, 2021.
In this article, we outline the history of the MDR and the events that accelerated this transformation. It also explains how EUDAMED emerged and what consequences can arise from delayed EUDAMED registrations.
How did the MDR come about?
MDR’s introduction was a direct response to significant safety gaps in the European medical device market. The PIP breast implant scandal made it clear that the old Medical Device Directive (MDD) was no longer sufficient to adequately ensure patient safety. Poly Implant Prothèse (PIP), a French manufacturer, used industrial silicone for its products for years instead of the more expensive medical-grade equivalent. Due to the inferior material, there was a significantly increased number of complications. This fraud went undetected for a long time. Contributing factors included announced audits and the lack of systematic post-market follow-up.
The scandal exposed fundamental weaknesses. These included a lack of transparency, insufficient market surveillance, and unclear responsibilities. The EU responded with a comprehensive reform. With the MDR, more extensive controls and greater transparency were introduced. It therefore emerged not only from the need for modern regulation considering new technologies, but explicitly also as a consequence of the PIP scandal.
With the MDR, a future-proof regulatory system was created that specifically addresses the weaknesses of the MDD and sustainably strengthens the protection of patients.
What role does EUDAMED play in this context?
Against this background, the purpose of EUDAMED becomes clear. The database is a direct consequence of the weaknesses revealed by the PIP scandal. At the time, authorities lacked a centralized, Europe-wide source of information. There was no suitable way to systematically link manufacturers, products, and certificates. Information was spread across numerous national systems and was difficult to compare.
EUDAMED was created to solve this problem. It serves as a central European database that maps the entire lifecycle of a medical device. This ranges from manufacturer registration to product and UDI data, as well as certificates, market surveillance, and incident reporting. For the first time, this creates a coherent overall picture that enables authorities to identify risks earlier and respond in a more coordinated manner. At the same time, the MDR pursues a clear transparency objective through EUDAMED. Certain information is no longer intended to be accessible only to authorities and professionals, but also to the public. Trust in the products is strengthened and pressure on manufacturers to consistently comply with their obligations is increased. EUDAMED is therefore a central instrument of the MDR.
The consequences of delayed EUDAMED entries for manufacturers
Transparency, one of the main reasons for the introduction of the MDR, is undermined when manufacturers do not register their products in EUDAMED in a timely manner. Consequences can be immediate. Under the MDR, registration is no longer a voluntary bonus but a central prerequisite for market access. Starting no later than November 28, 2026, products intended for the European market must be registered in EUDAMED. The six-month transition period ends on that date.
Without correct entries in the relevant EUDAMED modules, especially UDI and product registration, medical devices are considered not to have been properly placed on the market from a regulatory perspective. In practice, this means that products may not be newly placed on the market. This applies even if they are technically compliant and have a valid certificate. Market surveillance authorities can prohibit distribution, withdraw products from the market, or stop placing them on the market until registration is fully and correctly completed. For manufacturers, this can lead to supply interruptions, delays in market launches, and significant revenue losses.
In addition, nonconformities during audits or strict supervisory measures may follow. Economic operators such as importers and authorized representatives also come under pressure, as they share responsibility for the correct EUDAMED linkage of their manufacturers. Finally, missing registration also affects a company’s reputation. EUDAMED is intended to create transparency, and those who are not present or provide incomplete data signal a lack of appreciation for patient safety. In the long term, this can significantly undermine the trust of authorities, business partners, and customers.
Impact on other stakeholders
Business partners that may be affected include wholesalers and notified bodies. Under the MDR, wholesalers are obliged to verify that the products they distribute are properly registered and have valid certificates. If this is not the case, they quickly find themselves in a regulatory gray area. Products that are not correctly recorded in EUDAMED are considered not to have been placed on the market in compliance with regulations. Here too, distribution bans, regulatory actions, or orders to withdraw products may be imposed. This happens even if the root cause lies with the manufacturer, while the consequences remain the same.
Additional complexity arises from the role of notified bodies. They must clearly link products in EUDAMED with the issued MDR certificates. If the corresponding product data is missing or incomplete, certificates cannot be correctly assigned. This leads to inconsistencies, which in turn complicate audits or trigger inquiries from authorities.
What begins as an administrative omission quickly develops into a trust issue for manufacturers, wholesalers, and notified bodies alike.
Anyone who still wants to be compliant in time before the relevant deadlines should act now. With the mytracekey UDI Manager, you gain the necessary transparency and data quality to meet EUDAMED requirements not only on time, but sustainably.